A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.
Randomised trial in 29 patients with HFpEF, 13 weeks, against placeboDapagliflozin
Limit: Only 29 patients completed the protocol, limiting power to detect improved relaxation
Experiments in mice producing a progeria-linked protein in heart muscle cells found that restoring an RNA-marking protein partly reduced abnormal heart changes.Experiments in mice producing a progeria-linked protein in heart muscle cells found that restoring an RNA-marking protein partly reduced abnormal heart changes.
Experiments in Zmpste24−/− mice, 2 months, against AAV-cTnT-GFP-treated miceMechanisms
Limit: Reduced heart fibrosis does not directly demonstrate restored pumping function
Long-lived African turquoise killifish show ventricular enlargement, fibrosis, and reduced myocardial density with age rather than typical cardiomyocyte hypertrophy.Long-lived African turquoise killifish show ventricular enlargement, fibrosis, and reduced myocardial density with age rather than typical cardiomyocyte hypertrophy.
Exposure to environmental arsenic caused heart dysfunction via the p53 and p21 pathway, which quercetin treatment reversed in cultured rat cardiomyoblasts.Exposure to environmental arsenic caused heart dysfunction via the p53 and p21 pathway, which quercetin treatment reversed in cultured rat cardiomyoblasts.
The compound lowered senescence markers and improved heart function through SIRT3-driven DRP1 deacetylation in aged mice and cultured cardiomyocytes.The compound lowered senescence markers and improved heart function through SIRT3-driven DRP1 deacetylation in aged mice and cultured cardiomyocytes.